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1. Introduction
DNA double-strand break (DSB) is considered most critical type of DNA damage. In eukar‐
yote, DSB is repaired mainly through non-homologous end-joining (NHEJ) and homologous
recombination (HR). Our understanding on the molecular mechanisms of these DNA repair
mechanisms has been greatly deepened in the last two decades.
In NHEJ, DSB is first recognized by Ku protein (Fig.1 (1)), heterodimer consisting of Ku70 and
Ku86 (also known as Ku80), which in turn recruits DNA-PK catalytic subunit (DNA-PKcs)
(Fig.1 (2)). The comprex consisting of Ku70, Ku86 and DNA-PKcs is termed DNA-dependent
protein kinase (DNA-PK). When the DSB are not readily ligatable, processing takes place prior
to ligation (Fig.1 (3)). Processing might involve a number of enzymes depending on the shape
of each DNA end and compatibility of two ends to be ligated: Artemis nuclease, DNA
polymerase µ/λ, polynucleotide kinase/phosphatase (PNKP), Aprataxin (APTX) and Apra‐
taxin and PNKP-like factor (APLF, also known as PALF, C2orf13 or Xip1). DSBs are finally
joined by DNA ligase IV, which is in tight association with XRCC4 (Fig.1 (4)). XRCC4-like
factor (XLF, also known as Cernunnos), is essential at this step, especially when two ends are
not compatible.
In HR, a complex consisting of Mre11, Rad50 and Nbs1, termed MRN complex, is thought to
play two important roles in the initial stage (Fig.1 (1’)): recruitment of ATM (Fig.1 (2’’)) and
resection of one of the strands (Fig.1 (2’)). ATM is a protein kinase structurally similar to DNA-
PKcs. Although ATM is thought to phosphorylate a great number of proteins as revealed by
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phosphoproteomic analyses, the phosphorylation of histone H2AX at Ser139 is thought one of
the most important events, triggering signal transduction cascade involving mediator protein
like MDC1 and ubiquitin ligases like RNF8 and RNF168. As Mre11 bears 5’-3’ exonuclease
activity, MRN resects one of the DNA strands to generate single-stranded DNA (ssDNA),
which serves as a probe for the search for homology. Replication protein A (RPA) binds to
ssDNA (Fig.1 (2’)) and facilitate the formation of Rad51 filament in cooperation with BRCA2,
PALB2, Rad52 and Rad51 paralogues (Fig.1 (3’)). RPA also recruites ATRIP, which in turn
recruits ATR, another protein kinase structurally related to DNA-PK and ATM (Fig.1 (3’’)).
ATR phosphorylate checkpoint kinase Chk1 to initiate signal transduction pathway leading
to cell cycle checkpoints. Rad51 promotes strand exchange between homologous sequences
(Fig.1 (4’)). Template-dependent strand synthesis is proceeded by replication machinery
including PCNA and DNA polymerase δ and ε (Fig.1 (5’)). Finally, the junction of two DNA
molecules (Holliday’s junction) are resolved by nucleases Mus81-Eme1, ERCC1-XPF or SLX1-
SLX4 (Fig.1 (6’)). Alternatively, synthesized strand aneals with opposite end of DSB, detaches
from the temprate strand, followed by synthesis and ligation of complementary strand
(synthesis-dependent strand anealing; SDSA, not shown here).
Here, we will overview approaches to radiosensitization through the modification of DSB
repair enzymes.
Figure 1. DNA double-strand break repair mechanisms.
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2. DNA-PK, ATM and ATR kinases as targets for radiosensitizer
2.1. DNA-PK
DNA-PK was initially found in the extracts of HeLa cell, rabbit reticulocyte, Xenopus egg and
sea urchin egg (Walker et al., 1985) and was purified from Hela cell nuclei as a 300-350 kDa
protein, which is now called DNA-PKcs (Carter et al., 1990; Lees-Miller et al., 1990). Later it
was found that Ku is an essential component of DNA-PK (Dvir et al., 1992, 1993; Gottlieb and
Jackson, 1993). Furthermore, it was also shown that DNA-PK requires binding of DNA-PKcs
to DNA ends via Ku to be activated, suggesting its possible role in sensoring DSBs (Gottlieb
and Jackson, 1993). Ku86 was shown to be equivalent to XRCC5 (X-ray repair cross comple‐
menting) gene product, which is missing in X-ray sensitive rodent cell lines including xrs-5,
-6, XR-V9B and XR-V15B (Taccioli et al., 1994; Smider et al., 1994). Subsequently, DNA-PKcs
was found to correspond to XRCC7, which is deficient in scid mouse as well as several
radiosensitive cultured human and rodent cell lines (Kirchgessner et al., 1995; Blunt et al.,
1995; Peterson et al., 1995; Lees-Miller et al., 1995). DNA-PK is abundant in human cells and
its activity can be measured using synthetic peptides derived from p53 (Lees-Miller et al.,
1992), enabling extensive studies on its biochemical properties even before molecular cloning
of DNA-PKcs.
First reported selective inhibitor of DNA-PK is OK-1035, 3-cyano-5-(4-pyridyl)-6-hydrazono‐
methyl- 2-pyridone (Fig.2 A), which was found by screening of more than 10,000 microbial
extracts and synthetic compounds (Take et al., 1995). IC50 (50% inhibitory concentration) on
DNA-PK was 8 µM, which was more than 50-fold lower than that on other seven kinases
examined, although it was reported to be much higher, i.e., 100 µM, in others’ study (Stockley
et al., 2001). OK-1035 was shown to suppress adriamycin-induced p21 expression in cultured
human carcinoma cell at concentrations 500 - 2000 µM (Take et al., 1996) and also to retard the
repair of DSB measured by neutral single cell gel electrophoresis (comet) assay (Kruszewski
et al., 1998).
Sequence of DNA-PKcs revealed its similarity to phosphatidylinositol 3-kinase (PI3K) (Hartley
et al., 1995). This study also that fungal metabolite wortmannin (Fig.2 B), which had been
known as an inhibitor of PI3K, could inhibit DNA-PK (Hartley et al., 1995). IC50 of wortmannin
is reported to be 0.016 µM and 0.12 µM (Sarkaria et al., 1998; Izzard et al., 1999). It was also
shown that wortmannin binds covalently to DNA-PKcs and functions as non-competitive,
irreversible inhibitor of DNA-PK (Sarkaria et al., 1998; Izzard et al., 1999). Expectedly, a number
of studies have demonstrated radiosensitizing effects of wortmannin but there is a concern
whether the observed radiosensitization was really due to inhibition of DNA-PK. In this
regard, some studies showed that radiosensitization by these compounds could be observed
even in DNA-PKcs-deficient cells (Rosenzweig, et al., 1997; Hosoi et al., 1998), indicating that
radiosensitization by these compounds was not solely due to inhibition of DNA-PK. In
addition to ATM discussed next, PI3K-Akt pathway, which might be even more sensitive to
wortmannin, might be important to sustain cell survival after irradiation. On the other hand,
there are also studies showing that radiosensitization was not observed in DNA-PKcs deficient
cells (Chernikova, et al., 1999; Hashimoto, et al., 2003). These studies argue that, even if
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wortmannin affect PI3K or other kinase more potently than DNA-PK, the radiosensitizing
effect might be mainly due to inhibition of DNA-PK.
Figure 2. Strucuture of DNA-PK inhibitors.
Another PI3K inhibitor LY294002, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (Fig.2
C) was also shown to inhibit DNA-PK. In contrast to wortmannin, LY294002 competes with
ATP (Izzard et al., 1999). IC50 of LY294002 is reported to be 6 µM (Izzard et al., 1999). LY294002
was used as a leading compound to explore more potent and selective inhibitors of DNA-PK.
NU7026, 2-(morpholin-4-yl)-benzo[h]chromen4-one (Fig.2 D), was found as selective inhibitor
of DNA-PK (Veuger et al., 2003). IC50 of NU7026 was 0.23 µM for DNA-PK, 13 µM for PI3K
and >100 µM for ATM and ATR (Veuger et al., 2003). NU7026 sensitized cultured cells toward
radiation in a manner dependent on DNA-PK (Veuger et al., 2003). Synthesis and screening of
chromen-4-one library resulted in identification of NU7441 (Fig.2 E), 8-dibenzothiophen-4-yl-
2-morpholin-4-yl-chromen-4-one (Leahy et al., 2004; Hardcastle et al., 2005). IC50 of NU7441
was 0.014 µM for DNA-PK, 5.0 µM for PI3K and >100 µM for ATM and ATR (Leahy et al.,
2004). NU7441 sensitized cultured cells toward radiation and etoposide in a manner dependent
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on DNA-PK at 0.5 µM (Zhao et al., 2006). Screening of the derivatives of LY294002 also lead
to the identification of other selective inhibitors of DNA-PK; IC60211 (Fig.2 F, 2-Hydroxy-4-
morpholin-4-yl-benzaldehyde, IC50: 0.43 µM), IC86621 (Fig.2 G, 1-(2-Hydroxy-4-morpholin-4-
yl-phenyl) -ethanone, IC50: 0.12 - 0.17 µM), AMA37 (Fig.2 H, 1-(2-Hydroxy- 4-morpholin-4-yl-
phenyl)-phenyl-methanone, IC50: 0.27 µM) (Kashishian et al., 2003; Knight et al., 2004).
It was recently reported that NVP-BEZ235 (Fig.2 I, 2-methyl-2-(4-(3-methyl-2-oxo-8-(quino‐
lin-3-yl)-2,3-dihydro-1H -imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile), which had been
initially identified as a dual inhibitor for PI3K and mammalian target of rapamycin (mTOR)
(Maira et al., 2008), inhibited DNA-PK, ATM and ATR and sensitizes cells to ionizing radiation
(Toledo et al., 2011; Mukherjee et al., 2012). NVP-BEZ235 sensitized the cultured cells to
radiation and inhibited DSB repair, as shown by persistence of 53BP1 foci, to a greater extent
than NU7026 and KU55933 (Mukherjee et al., 2012). NVP-BEZ235 sensitized ATM-deficient
cells, i.e., fibroblast from ataxia telangiectasia patient, and also DNA-PKcs-deficient human
glioma cell M059J (Mukherjee et al., 2012), which could be due to dual inhibition of DNA-PK
and ATM. Moreover, inhibition of in cellulo phosphorylation mediated by DNA-PK and ATM
was achieved at low concentration, i.e., 0.1 - 0.5 µM, while the similar extent of inhibition was
achieved at 10 µM (Mukherjee et al., 2012).
Screening of a three-substituted indoline-2-one library lead to identification of SU11752 (Fig.
2 J) as selective DNA-PK inhibitor (IC50: 0.13 µM) (Ismail, et al., 2004). Vanillin, 4-hydroxy-3-
methoxybenzoaldehyde (Fig.2 K), was found to inhibit DNA-PK albeit at a relatively high
concentration, i.e., IC50 1500 µM (Durant and Karran, 2003). Screening of library of vanillin
derivatives lead to finding of more potent inhibitors, 4,5-dimethoxy-2-nitrobenzaldehyde
(DMNB, Fig.2 L) and 2-bromo-4,5- dimethoxybenzaldehyde (Fig.2 M), whose IC50 were 15 µM
and 30 µM, respectively (Durant and Karran, 2003).
DNA-PK can be inhibited by homopolymeric phosphorythioate oligonucleotides, suramin and
heparin (Hosoi et al., 2002). Inhibitory activities of homopolymeric phosphorothioate oligo‐
nucleotides on DNA-PK were independent of base composition but were dependent on length.
IC50 decreased as length increased: 0.975 µM for 12 mer and 0.013 µM for 36 mer (Hosoi et al.,
2002). IC50 of suramin and heparin were 1.7 µM and 0.27 µg ml-1, respectively (Hosoi et al.,
2002). Suramin sensitized cultured human cancer cell toward ionizing radiation but not to
ultraviolet radiation (Hosoi et al., 2004). Furthermore, suramin did not affect the radiation
sensitivity of scid cells, which are deficient in DNA-PK, indicating that radiosensitizating
effects of suramin were mediated through inhibition of DNA-PK (Hosoi et al., 2004).
Single chain antibody variable fragment (scFv) is another approach to achieve specific
inhibition of DNA-PK. ScFv was initially generated from existing murine monoclonal antibody
18-2, expressed in E. coli and introduced into the cell by microinjection (Li et al., 2003). The
epitope of scFv 18-2 was mapped within 2001-2025 region, which is outside of kinase domain
and thus ScFv 18-2 inhibited DNA-PK activity only modestly (Li et al., 2003). Nevertheless,
microinjection of scFv 18-2 resulted in the inhibition of NHEJ, indicated by persistence of γ-
H2AX foci and sensitized cells toward ionizing radiation (Li et al., 2003). However, the use of
scFv as clinical radiosensitization might be difficult without a method to deliver it efficiently
into the cell nucleus. ScFv 18-2 conjugated with nuclear localization signal was developed
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(Xiong et al., 2009). In more recent study, scFv was conjugated with folate and introduced into
the cell nucleus via folate receptor-mediated endocytosis and exhibited radiosensitization in
terms of clonogenic survival (Xiong et al., 2012). Another study screened a phage-displayed
library of humanized scFv and identified a new antibody against DNA-PKcs, anti-DPK3-scFv
(Du et al., 2010). Transfection of cDNA of anti-DPK3-scFv into human cancer cells resulted in
increased radiosensitivity with decreased repair capability (Du et al., 2010). It also sensitized
transplanted tumor on mice toward radiation (Du et al., 2010).
2.2. ATM
ATM, ataxia-telangiectasia mutated, was identified as the gene responsible for the genetic
disorder  ataxia  telangiectasia,  showing  similarity  to  PI3K  (Savitsky  et  al.,  1995).  Subse‐
quently similarity between ATM and DNA-PKcs,  suggesting ATM might also be a  pro‐
tein  kinase  rather  than  a  lipid  kinase  (Hartley  et  al.,  1995).  ATM  was  shown  to  be  a
protein kinase, which is activated by DNA damage and phosphorylates p53 at Ser15 (Ba‐
nin et al., 1998; Canman et al., 1998).
Figure 3. Structure of ATM inhibitors.
Like DNA-PK, ATM was also shown to be inhibited by wortmannin with IC50 of 0.15 µM
(Sarkaria et al., 1998). It was also shown that administration of wortmannin to cultured cell
phenocopies the defect of ataxia telangiectasia cell, e.g., defective accumulation of p53 (Price
and Youmell, 1996) and radioresistant DNA synthesis, which is thought to reflect defective
G1/S- or S-phase checkpoint (Hosoi et al., 1998; Sarkaria et al., 1998). Caffeine, which was
known to abrogate cell cycle checkpoint, was shown to inhibit ATM and ATR (Sarkaria et al.,
1999; Hall-Jakson et al., 1999). IC50 for ATM and ATR was 200 µM and 1,100 µM, respectively
(Sarkaria et al., 1999).
Selective inhibitors were found from the small molecule library of LY294002 derivatives
(Hickson, et al., 2004; Hollick et al., 2007). Among them KU-55933, 2-morpholin-4-yl-6-
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thialanthren-1-yl-pyran-4-one (Fig.3 B) showed inhibition of ATM with IC50 of 0.013 µM
(Hickson, et al., 2004). IC50 values for other PI3K-related kinases were greater than 1.8 µM,
which is approximately 200-fold higher than that for ATM (Hickson, et al., 2004). As in the
case of DNA-PK inhibitors, morpholine group is important for inhibitory activity, as KU-58050,
in which morpholine group was replaced by piperidine group was much less effective: IC50
was 300 µM (Hickson, et al., 2004). KU-55933 inhibited in cellulo phosphorylation of ATM
substrates, e.g., p53 at Ser15 and histone H2AX at Ser139, 10 µM induced by ionizing radiation,
but not that induced by ultraviolet irradiation (Hickson, et al., 2004). Even at lower concen‐
tration, i.e., 0.3 µM, the inhibition of p53 phosphorylation was significant, although there was
trace amount of residual phosphorylation (Hickson, et al., 2004). It was also shown that
KU-55933 sensitized cultured cell to ionizing radiation and to radiomimetic compounds, e.g.,
etoposide and doxorubicin but did not alter the sensitivity of fibroblast from ataxia telangiec‐
tasia patients to ionizing radiation (Hickson, et al., 2004). Futhermore, KU-55933 was found to
suppress HIV infection (Lau et al., 2005).
Modification of KU-55933 lead to identification of KU-60019 (Fig.3 C), 2-((2R, 6S)-2, 6-Dimeth‐
yl-morpholin-4-yl)-N-[5-(6-morpholin-4- yl-4-oxo-4H-pyran-2-yl)-9H-thioxanthen-2-yl]-
acetamideas a more potent inhibitor of ATM (Golding et al., 2009). IC50 of KU-60019 for ATM
was 0.0063 µM, whereas IC50 values for DNA-PKcs and ATR were 1.7 µM and >10 µM,
respectively (Golding et al., 2009). KU-60019 mostly abolished ionizing radiation-induced
phosphorylation of p53 at Ser15 and Chk2 at Thr68 at 1 to 3 µM, whereas > 10 µM concentration
of KU-55933 was required to obtain similar extent of inhibition (Golding et al., 2009). KU-60019
at 1 µM showed similar extent of radiosensitization to KU-55933 at 10 µM (Golding et al., 2009).
Independent screening of chemical library lead to identification of CP466722, 2-(6,7-dime‐
thoxyquinazolin-4-yl)-5- (pyridin-2-yl)-2H-1,2,4-triazole-3-amine, as a novel inhibitor of ATM
(Rainey, et al., 2008). CPP466722 inhibited in cellolo phoshorylation of ATM at Ser1981, SMC1
at Ser957 and Chk2 at Thr68 but not affected the phosphorylation events, which are thought
to be mediated through other PI3K-related kinases (Rainey, et al., 2008). CPP466722 sensitized
cultured cells to radiation to a similar extent to KU-55933 (Rainey, et al., 2008).
CGK733 was reported to be a dual inhibitor of ATM and ATR, but the report was retracted
thereafter because of fabrication. Even after the retraction, CGK733 was marketed as an
inhibitor of ATM and ATR and several studies used CGK733 to show the involvement of ATM
and/or ATR in response to DNA damage caused by a variety of agents. On the other hand,
however, there is a report that this compound did not affect ATM and ATR kinase as shown,
respectively, by ionizing radiation-induced phosphorylation of ATM at Ser1981 and Chk2 at
Thr 68 and by ultraviolet radiation-induced phosphorylation of Chk1 at Ser317 (Choi et al.,
2011, and references therein).
2.3. ATR
ATR was initially identified as a molecule structurally related to human ATM and yeast Rad3
(Cimprich et al, 1996; Keegan et al., 1996). ATR was then shown to be a protein kinase, which
is capable of phosphorylating itself and p53 at Ser15 (Canman et al., 1998). ATR is thought to
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be a sensor of single-stranded DNA (ssDNA), binding to RPA (Replication Protein A) via
ATRIP (ATR-interacting protein) (Zou and Elledge, 2003).
Despite of its structural similarity to DNA-PKcs, ATM and PI3K, ATR appeared refractory to
wortmannin inhibition: IC50 of wortmannin for ATR was 1.8 µM, which was 10- to 100-fold
higher than that for DNA-PKcs and ATM (Sarkaria et al., 1998). Selective inhibitors of ATR
emerged recently.
Figure 4. Structure of ATR inhibitors
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Schisandrin B is an active ingredient of Fructus schisandrae, which has been used in tradi‐
tional Chinese medicine to treat hepatitis and myocardial disorders (Fig.4 A). Schisandrin
B was found to inhibit ATR (Nishida et al., 2009). IC50 of Schisandrin for ATR and ATM
were,  respectively,  7.25 µM and 1,700 µM and DNA-PK, PI3K and mTOR were not  in‐
hibited  up  to  ~100  µM (Nishida  et  al.,  2009).  Schisandrin  B  sensitized  cultured  human
cells to ultraviolet radiation and ionizing radiation at concentrations 1 -  30 µM (Nishida
et al., 2009). Sensitization was not observed in cells from Seckel patient, who harbor mu‐
tation in ATR gene (Nishida et al.,  2009), showing that the sensitizing effect is mediated
through ATR.
Library of 623 compounds, which had exhibited some inhibitory effects on PI3K, was screened
for their effects on in cellulo phosphorylaiton of H2AX stimulated by ATR-activating domain
of TopBP1 (Toledo et al., 2011). This screening identified NVP-BEZ235 (Fig.4 B) and ETP-46464
(Fig.4 C) (Toledo et al., 2011). Whereas NVP-BEZ235 also inhibited DNA-PK and ATM (see
above), ETP-464 did not affect DNA-PK and ATM (Toledo et al., 2011). These compounds
mostly inhibited the phosphorylation in cellulo of H2AX and other ATR substrates, e.g., Chk1,
even at 0.1 - 0.5 µM (Toledo et al., 2011).
High throughput screening of ATR by in vitro kinase assay identified 3-amino-N,6-diphe‐
nylpyrazine-2-carboxamide  (Charrier  et  al.,  2011).  IC50  of  this  compounds  for  ATR  was
0.62 µM, whereas that  for  ATM and DNA-PK was > 8 µM (Charrier  et  al.,  2011).  Then
the derivatives of this compound were synthesized and subjected to test for ATR inhibi‐
tion.  VE-821,  3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide,  was
found as most potent and selective inhibitor of ATR (Charrier et al., 2011). IC50 of VE-821
for ATR was 0.026 µM, whereas that for ATM and DNA-PK was > 8 µM and 4.4 µM, re‐
spectively (Charrier et al., 2011).
NU6027, 2,6-diamino-4-cyclohexyl-methyloxy-5-nitroso-pyrimidine, was initially developed
as an inhibitor of cyclin- dependent kinases (CDKs) (Arris et al, 2000). NU6027 was recently
found, however, to inhibit ATR more potently than CDK2 (Peasland et al., 2011). NU6027
inhibited in cellulo phosphorylation of Chk1 at Ser345 with IC50 of 6.7 µM, whereas autophos‐
phorylation of DNA-PKcs at Ser2056 and ATM at Ser1981 were not affected at 10 µM (Peasland
et al., 2011). NU6027 sensitized cultured cells to hydroxyurea and cisplatin, but this effect was
not observed in ATR-knocked down cells, showing that sensitization was mediated through
ATR (Peasland et al., 2011).
It  might be added that p53-deficient cells,  than p53-proficient cells,  exhibited greater ex‐
tent of sensitization toward ionizing radiation and other DNA damaging agents by ATR
inhibitors NVP-BEZ235, ETP-46464 (Toledo et al.,  2011), VE-821 (Reaper et al.,  2011) and
NU6027  (Peasland  et  al.,  2011).  This  could  be  due  to  simultaneous  inactivation  of  two
checkpoint pathways mediated through ATM and ATR, respectively, the former of which
involves  p53.  As  most  of  cancer  cells  lose  p53  function,  inhibition  of  ATR  might  be  a
promising approach to achieve selective killing of cancer cells,  minimizing the effects to
surrounding normal cells.
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3. Other DSB repair enzymes as targets for radiosensitizer
3.1. MRN complex
Mirin, Z-5-(4-hydroxybenzylidene)-2-imino-1,3-thiazolidin-4-one (Fig.5), was identified in a
screen for smalll molecules inhibiting MRN-ATM pathway (Dupre et al., 2009). Restriction
enzyme-digested plasmid was added to cell-free extract prepared from Xenopus laevis egg in
96-well format and the phosphorylation of H2AX-mimicking peptide was quantified. Ap‐
proximately 10,000 compounds, which had exhibited inhibition of p53 activity or inteference
with mitosis and spindle dynamics, were subjected to screen. Mirin inhibited H2AX phos‐
phorylation in Xenopus laevis egg cell free extract with an IC50 of 66 µM and also autophos‐
phorylation of ATM at Ser1981 in human cells within 25 - 100 µM range (Dupre et al., 2009).
Mirin inhibited nuclease activity of Mre11, but did not affect DNA binding or DNA tethering
activity of MRN complex (Dupre et al., 2009). Mirin also abrogated G2/M checkpoint, reduced
homologous recombination and showed radiosensitizing effects in cultured human cells
within 25 - 100 µM range (Dupre et al., 2009).
Figure 5. Structure of Mirin.
3.2. DNA ligase IV
Inhibitors of DNA ligases were searched in a database of 1.5 million commercially available
low molecular weight chemicals by computer-aided drug design approach based on crystal
structure of DNA ligase I (Chen et al., 2008). In this approach, L82 ((E)-2-((2-(2-((3,5-dibromo-4-
methylphenyl)amino)ethyl)hydrazono)methyl)-4-nitrophenol, Fig.6 A), inhibiting DNA
ligase I, L67 ((E)-4-chloro-5-(2-(4-hydroxy-3-nitrobenzylidene)hydrazinyl)pyridazin-3(2H)-
one, Fig.6 B), inhibiting DNA ligases I and III, and L189 ((E)-6-amino-5-(benzylideneamino)-2-
mercaptopyrimidin-4-ol, Fig.6 C), inhibiting DNA ligases I, III and IV, were identified. None
of them inhibited the activity of T4 ligase (Chen et al., 2008). Kinetic alalysis indicated that,
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whereas L82 is non-competitive inhibitor, L67 and L189 competes with DNA substrate (Chen
et al., 2008). L67 sensitized cultured human cancer cells to methylmethansulfonate at 3 µM
(Chen et al., 2008). Similarly, L189 sensitized cultured human cancer cells to ionizing radiation
at 20 µM (Chen et al., 2008). It might be noted that the sensitizing effects of L67 and L189 were
not observed in non-cancer cells, suggesting is selective effects on cancer cells (Chen et al.,
2008). These compounds can be a leading compounds for the development of more potent and/
or more selective inhibitors of DNA ligases.
Figure 6. Strucutre of DNA ligase inhibitors.
3.3. DPYD as a new target
Gimeracil, 5-chloro-2,4-dihydroxypyridine (Fig.7), is an inhibitor of dihydropyrimidine
dehydrogenease (DPYD) and used as a component of oral anti-cancer medicine S-1, in order
to suppress degradation of 5-fluorouracil. The results of clinical trial of concurrent chemora‐
diotherapy using S-1 suggested possible radiosensitizing effect of S-1. Gimeracil increased
radiosensitivity of cultured human cancer cells of various origin within 200 – 5,000 µM, being
maximal within 1,000 – 5,000 µM range (Takagi et al., 2010). Cell lines deficient for DNA-PKcs
or Ku86 were sensitized by gimeracil to radiation even to a greater extent than respective
control cells (Takagi et al., 2010). On the other hand, radiosensitiztion was not observed in cell
lines deficient for XRCC3, NBS1 or FANCD2 (Takagi et al., 2010). These observations collec‐
tively suggested that gimeracil exert radiosensitizing effects through inhibition of HR-
mediated DSB repair. Gimeracil reduced the frequency of homologous recombination of
chromosomal substrate including the restriction site of I-SceI by approximately 15% (Takagi
et al., 2010). Gimeracil reduced the formation of ionizing radiation-induced foci of Rad51 and
RPA but increased that of Nbs1, Mre11, Rad50 and FancD2 (Sakata et al., 2011). This observa‐
tion suggested that gimeracil might have inhibited the step after strand resection by Mre11-
Rad50-Nbs1 complex but before the loading of RPA and Rad51 onto single-stranded DNA.
Although the role of DPYD in HR has not been described, treatment with siRNA for DPYD
sensitized cells to ionizing radiation to a similar extent to gimeracil and also diminished the
radiosensitization by gimeracil (Sakata et al., 2011). These results collectively indicate that
gimeracil exerts radiosensitizing effects through inhibition of DPYD, which might have a novel
role in HR.
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Figure 7. Structure of gimeracil.
4. Radiosensitization by hyperthermia
Hyperthermia, heating parts of body at 40 - 45 oC, has been used to treat cancer mostly
combined with ionizing radiation. Hyperthemia is known to sensitize cells to ionizing
radiation, inhibiting the repair of DNA damages including DSBs, but the molecular mechanism
of radiosensitization by hyperthermia has remaind to be clarified.
Effects of hyperthermia on DNA polymerases α and β have been studied for a long time. These
studies suggested that DNA polymerase β was sensitive to hyperthermia and its inactivation
was correlated to radiosensitization as well as to cell killing (Spiro et al., 1982). Later it was
reported that DNA polymerase β knocked out cells or overexpressed cells exhibited radio‐
sensitization by hyperthermia indifferent from control cells (Raaphorst et al., 2004). Elucida‐
tion of DSB repair mechanisms through NHEJ and HR provided clues to the mechanisms of
radiosensitization by hyperthermia.
Among essential factors in NHEJ, Ku is shown to be affected by hypethermia. Purified DNA-
PK lost its activity upon incubation at 44°C for 5 - 30 min (Matsumoto et al., 1997). When DNA-
PKcs and Ku were heated separately, heating of Ku, but not DNA-PKcs, lead to decrease in
DNA-PK activity, suggesting that Ku, rather than DNA-PKcs, is heat sensitive component
(Matsumoto et al., 1997). Inactivation of DNA-PK activity by hyperthermia was observed also
in cellulo, i.e., when culture cells were heated at 44 – 47°C (Burgman et al., 1997; Ihara et al.,
1999; Umeda et al., 2003). It might be noted, however, that the extent of the loss of DNA-PK
was greatly different between mouse, hamster and human cell, being greatest in mouse and
least in human (Umeda et al. 2003). In murin cells, significant loss of DNA-PK activity was
observed at lower tempertures, i.e., 41°C or 42°C (our unpublished observations). DNA-PK
activity could be restored by mixing the lysate of heated cells with the lysate of DNA-PKcs-
deficient cells, but not with Ku86-deficient cells, indicating that in cellulo inactivation of DNA-
PK by hyperthermia might be also due to the property of Ku rather than DNA-PKcs (Ihara et
al., 1999). Moreover, Ku was identified as constitutive heat shock element-binding factor,
CHBF, whose activity was lost by hyperthermia, allowing the binding of HSF1 (Kim et al.,
1995). DNA binding activity of Ku correlated with extent of radiosensitization by hyperthermia
(Burgman et al., 1997). Reduced solubility of Ku in aquaous buffer after hyperthermia was also
reported, which might reflect aggregation (Beck and Dynlacht, 2001). However, the hypothesis
New Research Directions in DNA Repair650
that radiosensitization by hyperthermia is due to inactivation of Ku or DNA-PK has been
challenged by genetic studies, showing that cells deficient for Ku or DNA-PKcs could be
radiosensitized by hyperthermia to a similar extent or even to a greater extent than control
cells (Kampinga et al., 1993; Raaphorst et al., 1993; Woudstra, et al, 1999, Raaphorst et al.,
2004), although there are studies, in contrast, showing no or reduced radiosensitization in Ku-
or DNA-PKcs-deficient cells (Iliakis and Seaner, 1990; O’Hara et al., 1995). Moreover, chicken
lymphocyte DT40 derivative lacking Ku70 and Rad54, therefore, deficient in both of NHEJ and
HR, still showed radiosensitization by hyperthermia (Raaphorst et al., 2004; Yin et al., 2004).
There  is  also  accumulating studies  on the  effects  of  hyperthermia  on MRN complex.  It
was  initially  found  that  Mre11,  Rad50  and  Nbs1  exported  from  nucleus  to  cytoplasm
upon hyperthemia at  42.5°C or 45.5°C (Zhu et  al.,  2001;  Seno and Dynlacht,  2004).  This
nuclear export of MRN complex increased when cells were irradiated prior to hyperther‐
mia  (Zhu et  al.,  2001;  Seno and Dynlacht,  2004).  Similar  phonomenon was  observed in
mild hyperthermia at  41.1°C (Xu et  al.,  2002).  However,  in a  recent  study,  inhibition of
nuclear export of MRN complex by leptomycin B did not diminish radiosensitization by
hyperthermia at  45.5°C for  10 min (Dynlacht  et  al.,  2011).  It  was also shown,  neverthe‐
less, that ATLD cells,  which have mutated in Mre11, did not show radiosensitization by
hyperthermia at  41.5°C for 2 hrs or at  45.5°C for 10 min (Dynlacht et  al.,  2011).  On the
other  hand,  radiosensitization  by  hyperthermia  was  observed  in  NBS  cells  and  Rad50-
knocked down cells (Dynlacht et al.,  2011). Exonuclease activity of Mre11 was decreased
to ~10% by 42.5°C treatment for 15 min (Dynlacht et al.,  2011). These results collectively
indicate Mre11 as target for radiosensitization by hyperthermia.
Hyperthermia is shown to affect BRCA1 and BRCA2. Heating cultured human cancer cells at
42°C for 1 - 2 hrs or more decreased the amount of BRCA1 (Ma et al., 2003). It might be caused
by protein degradation, but various inhibitors of proteases, so far as tested, failed to suppress
the decrease of BRCA1 (Ma et al., 2003). Alternatively, it might be caused by protein aggrega‐
tion and reduced solubility in aqueous buffers. It was also shown that BRCA1 deficient cells
were sensitive to hyperthermia (Ma et al., 2003). Recent study reported the degradation of
BRCA2 induced by mild hyperthermia at 41°C to 42.5°C (Krawczyk et al., 2011). Rad54-
deficient ES cells and cells treated with XRCC3 siRNA were not radiosensitized by mild
hyperthermia (Krawczyk et al., 2011). Furthermore, mild hyperthermia showed synthetic
lethality with PARP-1 inhibitor oraparib, like BRCA2 deficient cancer cells (Krawczyk et al.,
2011). These data collectively indicated BRCA2 as a major target of mild hyperthermia.
Obviously,  hyperthermia  inactivates  many  enzymes  and  induces  aggregation  of  many
proteins. In this regard, hyperthermia is not specific on certain enzyme, unlike inhibitors
described above. However, susceptiblity to inactivation by hyperthermia might be greatly
different among proteins. The extent of radiosensitization by hyperthermia can be greatly
infuluenced by many factors, e.g., cell type, genetic background, physiological conditions,
heating temperature,  duration of  heating,  sequence of  heating and radiation and the in‐
terval between them. Further studies would be required to examine the effects of hyper‐
thermia  on  various  repair  enzymes  and  and  its  relationship  to  radiosentizing  effects
under various conditions.
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5. Concluding remarks and future perspectives
Because of great advances in our understanding of the moleuclar mechanisms of DSB repair
in past two decades, extensive studies have been done to achieve radiosensitization by
modification of DSB repair molecules. Especially, a number of inhibitors have been developed
for DNA-PK, ATM and ATR protein kinases. We saw here that preceeding studies on DNA-
PK and on PI3K greatly facilitated the studies on ATM and ATR. It might be underscored that
LY294002, preexisting inhibitor of PI3K, served as a leading compound and enabled the finding
of potent and specific inhibitors like NU7441 and KU-55933.
Studies toward the clinical application of these compounds are underway. Preclinical studies
of pharmacokinetics and metabolism in mice were conducted for NU7026 and NU7441. In the
case of NU7026, the radiosensitizing effect on cultured cancer cell was marginal upon the
treatment at 10 µM for 2 hrs and could be increased by extending the treatment time up to 24
hrs (Nutley et al., 2005). On the other hand, however, NU7026 underwent rapid plasma
clearance in mice, presumably because of oxidation and ring opening of morpholino group
(Nutley et al., 2005). It was estimated that NU7026 should be administered four times per day
at 100 mg/kg intraperitoneally in order to obtain radiosensitization (Nutley et al., 2005). In the
case of NU7441, the radiosensitizating effect on cultured cancer cell could be obtained by
treatment at 1 µM for 1 hr (Zhao et al., 2006). The concentration of NU7441 required for
radiosensitization could be maintained within tumor tissues for more than 4 hrs at nontoxic
dose (Zhao et al., 2006). The administration of etoposide and NU7441 to mice bearing human
tumor xenografts synergistically delayed tumor growth, indicating the chemosensitizing effect
of NU7441 in vivo (Zhao et al., 2006). Studies are still going on to obtain compounds with better
characteristics, e.g., higher aquaous solubility (Cano et al., 2010).
Search for inhibitors of enzymes other than protein kinases has been difficult due to the absence
of assay system suitable for highthroughput screening. However, inhibitors of other enzymes,
i.e., Mre11 nuclease and DNA ligase IV have been developed, although few at present. Now
these compuonds are obtained, more potent and specific inhibitors can be obtained by
molecular evolution as in the case of DNA-PK, ATM and ATR protein kinases. Additionally,
search for other inhibitors will be greatly facilitated by an aid of computer-based structural
prediction and drug designing.
In addition to use of each chemicals alone, use of two or more chemicals together to inhibit
two pathways of DSB repair or one of them with other repair mechanisms, which is called
synthetic lethality approach, will be promising. Successful example is shown in the treatment
of cancers arisen in the carriers of BRCA2 mutation with PARP-1 inhibitors. When PARP-1,
which is essential for single-strand break (SSB) repair, is inactivated, SSB is converted to DSB,
which requires BRCA2 to be repaired. As BRCA2 mutation is heterozygotic, normal cells retain
BRCA2 function. On the other hand cancer cells have lost BRCA2 function and, therefore,
shows extreme sensitivity to increased sensitivity to converted DSBs. This is instructive also
to find a means to discriminate cancer cells and normal cells. As described in the previous
section, although hyperthemia is not an approach to target a certain molecule specifically, it
did show synthetic lethal effects with PARP-1 inhibitor. These examples underscores the
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importance of the choice of agents based on the thorough consideration of biological charac‐
teristics and genetic background of each cancer and patient. In addition to continuing persuit
for the new radiosensitizing agents, extensive studies would be necessary regarding combi‐
natorial approach and personalized medicine.
Note
We apologize for not citing many important literatures because of space limitation.
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